Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY) reporting forecast-beating earnings.

View more earnings on IBB

Intec Pharma Ltd (NASDAQ: NTEC) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS) lost much of their market value this week on clinical trial setbacks.

The following are some of the key biotech catalysts in the upcoming week:

Conferences

• 2nd Annual Biotechnology Congress: July 29-30 in Chicago.

• 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden.

• 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago.

Clinical Trial Readouts (mid-2019 releases)

• Immunic Inc (NASDAQ: IMUX): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis.

• Conatus Pharmaceuticals Inc (NASDAQ: CNAT): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.

• Alkermes Plc (NASDAQ: ALKS): Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis.

• IMMUTEP LTD/S ADR (NASDAQ: IMMP): initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer.

• Aevi Genomic Medicine Inc (NASDAQ: GNMX): Phase 1b data for AEVI-002 in pediatric onset Crohn's disease.

• Tricida Inc (NASDAQ: TCDA): 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease.

• Curis, Inc. (NASDAQ: CRIS): Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma.

• Ultragenyx Pharmaceutical Inc (NASDAQ: RARE): Phase 1/2 data from a second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 and Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase.

• Allakos Inc (NASDAQ: ALLK): Phase 2 top-line data for AK002 in eosinophilic gastritis.

• Leap Therapeutics Inc (NASDAQ: LPTXV): Phase 1/2 data for DKN-01 plus Keytruda in esophagogastric adenocarcinoma.

• Cidara Therapeutics Inc (NASDAQ: CDTX): Phase 2 data for rezafungin in candidemia.

• Akcea Therapeutics Inc (NASDAQ: AKCA): Phase 3 data for volanesorsen in familial partial lipodystrophy.

• Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) and Zai Lab Ltd (NASDAQ: ZLAB): Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors

• ZEALAND PHARMA/S ADR (NASDAQ: ZEAL): Phase 1b data for dasiglucagon in obesity/diabetes.

• Aclaris Therapeutics Inc (NASDAQ: ACRS): Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis.

• AnaptysBio Inc (NASDAQ: ANAB): Phase 2 data for ANB019 in generalized pustular psoriasis.

• Spark Therapeutics Inc (NASDAQ: ONCE): additional Phase 1/2 data for SPK-8011 in hemophilia A

Earnings

Monday, July 29

• Medpace Holdings Inc (NASDAQ: MEDP) (before the market open)

• Alimera Sciences Inc (NASDAQ: ALIM) (after the market close)

• Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the market close)

• Silk Road Medical Inc (NASDAQ: SILK) (after the market close)

Tuesday, July 30

• Eli Lilly And Co (NYSE: LLY) (before the market open)

• Iradimed Corp (NASDAQ: IRMD) (before the market open)

• Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)

• Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open)

• Merck & Co., Inc. (NYSE: MRK) (before the market open)

• Incyte Corporation (NASDAQ: INCY) (before the market open)

• Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (before the market open)

• NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)

• Pfizer Inc. (NYSE: PFE) (before the market open)

• Amgen, Inc. (NASDAQ: AMGN) (after the market close)

• AtriCure Inc. (NASDAQ: ATRC) (after the market close)

• EXACT Sciences Corporation (NASDAQ: EXAS) (after the market close)

• T2 Biosystems Inc (NASDAQ: TTOO) (after the market close)

• BioTelemetry Inc (NASDAQ: BEAT) (after the market close)

• Gilead Sciences, Inc. (NASDAQ: GILD) (after the market close)

• Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (after the market close)

• Veracyte Inc (NASDAQ: VCYT) (after the market close)

Wednesday, July 31

• Amarin Corporation plc (NASDAQ: AMRN) (before the market open)

• Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open)

• United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)

• Nuvectra Corp (NASDAQ: NVTR) (after the market close)

• ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the market close)

• Exelixis, Inc. (NASDAQ: EXEL) (after the market close)

• DexCom, Inc. (NASDAQ: DXCM) (after the market close)

• Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the market close)

• MacroGenics Inc (NASDAQ: MGNX) (after the market close)

• Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the market close)

• SurModics, Inc. (NASDAQ: SRDX) (after the market close)

Thursday, Aug. 1

• Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open)

• Akorn, Inc. (NASDAQ: AKRX) (before the market open)

• ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)

• Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open)

• Clovis Oncology Inc (NASDAQ: CLVS) (before the market open)

• Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)

• Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open)

• Insmed Incorporated (NASDAQ: INSM) (before the market open)

• Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open)

• Genomic Health, Inc. (NASDAQ: GHDX) (after the market close)

• Acorda Therapeutics Inc (NASDAQ: ACOR) (after the market close)

• Emergent Biosolutions Inc (NYSE: EBS) (after the market close)

• BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the market close)

• Coherus Biosciences Inc (NASDAQ: CHRS) (after the market close)

• Kindred Biosciences Inc (NASDAQ: KIN) (after the market close)

• Bio-Rad Laboratories, Inc. (NYSE: BIO) (after the market close)

• Geron Corporation (NASDAQ: GERN) (after the market close)

• Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the market close)

• CareDx Inc (NASDAQ: CDNA) (after the market close)

• Globus Medical Inc (NYSE: GMED) (after the market close)

• Verastem Inc (NASDAQ: VSTM) (after the market close)

• Ultragenyx (after the market close)

• Kura Oncology Inc (NASDAQ: KURA) (after the market close)

Friday, Aug. 2

• Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)

IPO

Rapt Therapeutics, a biotech company developing therapies for inflammatory diseases and cancer, is set to offer 5 million shares at an estimated price range of $14-$16. The company proposes to list its shares on the Nasdaq under the ticker symbol "RAPT."

See more from Benzinga

• The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

• Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA

• The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.